Abstract: A hydrogen storage and release arrangement comprising a vessel having a first end, a second end and an interior volume. The arrangement includes a first set of tubes extending into the interior volume from the first end of the vessel. Tubes of the first set of tubes each comprise a metal hydride. The arrangement further includes a second set of tubes, where tubes of the second set of tubes each include a metal hydride. The metal hydride of the first set of tubes and the metal hydride of the second set of tubes are arranged to absorb and desorb hydrogen gas in response to temperature changes caused by heat exchange fluid. The second set of tubes extends into the interior volume from the second end of the vessel. The embodiments herein also relate to use of a hydrogen storage and release arrangement and a method for storing and releasing hydrogen.

Abstract: A hydrogen storage and release arrangement comprising a vessel having a first end, a second end and an interior volume. The arrangement includes a first set of tubes extending into the interior volume from the first end of the vessel. Tubes of the first set of tubes each comprise a metal hydride. The arrangement further includes a second set of tubes, where tubes of the second set of tubes each include a metal hydride. The metal hydride of the first set of tubes and the metal hydride of the second set of tubes are arranged to absorb and desorb hydrogen gas in response to temperature changes caused by heat exchange fluid. The second set of tubes extends into the interior volume from the second end of the vessel. The embodiments herein also relate to use of a hydrogen storage and release arrangement and a method for storing and releasing hydrogen.

Abstract: Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.

Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.

Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.

Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.